



WiSE[®] Device Update

October 2022

Background

EBR has identified a potential increased rate of battery depletion in some WiSE® systems

WiSE® transmitter update

- Ongoing technical assessments have identified a potential current leakage in some WiSE® transmitters
- This can lead to faster battery depletion in affected systems
- If impacted, the device will continue to function normally until battery is depleted
- Clinically confirmed in 1 patient (0.8%) and suspected in another 7 (6.3% confirmed + suspected)

Solution

- ✓ EBR is working closely with clinical sites and regulatory bodies to provide patient management recommendations
- ✓ Issued Technical Notification to customers in line with regulations and industry best practice
- ✓ Manufacturing solutions already identified and working towards implementation


No impact to SOLVE trial

- ✓ Does not affect timing of headline results of SOLVE, which remain on track to be released in H1 2023
- ✓ Final PMA submission to the FDA planned for H2 2023
- ✓ Strong cash position sufficient to support EBR through to FDA approval and commercialisation

Pivotal SOLVE trial unaffected

EBR does not expect this development to impact the timing or data of headline results for the SOLVE trial

Interim enrolment completed



183rd patient enrolled as of 30th June 2022

Timing and results unaffected

- **H1 2023 - Headline results**
EBR does not expect this issue to impact headline data for the SOLVE trial and remains confident that results will be released on schedule
- **H2 2023 - PMA submission to FDA**
PMA submission to the FDA is expected in H2 2023, which will include the necessary changes to design and manufacturing processes
- **H2 2024 - Commercialisation in US**
Clear and targeted pathway to commercialisation remains unaffected, targeting an initial addressable market of US\$2.5 billion

Funding and operations

EBR has sufficient capital to support the company through to FDA approval and commercialisation



Strong cash position

- ✓ EBR remains well funded with **US\$79.3m cash as at 30 June 2022**
- ✓ **EBR does not expect any material changes** to cash requirements to resolve this issue
- ✓ **Company retains funding flexibility** to execute on its clinical and commercialisation objectives



Defined operational pathway

- ✓ Solution identified with implementation to be finalised
- ✓ Continues **to engage with regulatory bodies** as part of consultative approach
- ✓ Technical Notice issued containing patient management recommendations
- ✓ Enrolment in TLC and ACCESS studies subject to resolution of transmitter issue



Commercialisation

- ✓ EBR intends **to re-apply for CE mark** in Europe under new MDR provisions
- ✓ European commercialisation will **commence following US as planned**
- ✓ EBR has necessary cash to reach expected commercialisation in 2024

Advantages of WiSE®

WiSE® addresses the shortcomings of traditional pacemakers

Wireless


Eliminates lead complications such as placement difficulty, blood clots, unintended nerve stimulation, dislodgement, extraction and repositioning.

Endocardial

Delivers pacing directly to the inside of the left ventricle – considered to be more physiologic.

Customised

Tailored therapy – endocardial pacing provides a greater selection of stimulation sites which may lead to better patient outcomes.



Disclaimer

The material contained in this document is a presentation of general information about the activities of EBR Systems, Inc. (ASX:EBR) (ARBN 654 147 127) and its subsidiaries (“EBR”) current as at the date of this presentation. It should be read in conjunction with EBR’s periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at www.asx.com.au.

The information in this presentation is provided in a summary form, does not purport to be complete and should not be relied upon as advice for investment purposes. This presentation is for information purposes only and is not financial product advice or a recommendation to acquire EBR securities. This presentation does not take into account the investment objectives, financial position or needs of any particular investor. Independent advice should be sought before making any investment decision.

The information in this presentation has been prepared by EBR in good faith and with due care, but the EBR does not make any representation or warranty, express or implied, as to the fairness, accuracy, correctness or completeness of the information, opinions or conclusions contained in this presentation. The information in this presentation is subject to change without notice and unless required by law, EBR assumes no obligation to update this presentation or its contents for any matter arising or coming to EBR’s notice after the date of this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management’s current expectations and beliefs. Such statements are typically identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, ‘anticipates’, ‘intends’ and other similar words. These statements are subject to risks and uncertainties that are difficult to predict and are based on assumptions as to future events that may not prove accurate. Actual results

may differ materially from what is expressed in this presentation.

To the maximum extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining to act as a result of this presentation or its contents is accepted by EBR or any of its officers, employees or agents.

The distribution of this presentation outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in Australia, the United States or any other jurisdiction.

Investors should note that this presentation may contain unaudited financial information that has been prepared by EBR’s management. EBR’s results are reported under US GAAP. Certain financial data in this presentation is “non-IFRS financial information” under Regulatory Guide 230 (Disclosing non-IFRS financial information) published by ASIC. All values are stated in U.S. dollars unless otherwise stated.

EBR’s CHES Depositary Interests (“CDIs”) are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.